CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 168 enrolled
Drug / intervention
50 mg of KX2-391 Ointment 1% +1 moredrug
Likely dose
50 mg of KX2-391 Ointment 1%from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02838628
NCT02838628Phase 2Completed
CompareCT.gov

A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment 1% in Subjects With Actinic Keratosis on the Face or Scalp

Almirall, S.A.·interventional·Posted Jul 20, 2016·Updated Apr 14, 2021

In Brief

A Phase 2 clinical trial evaluating 50 mg of KX2-391 Ointment 1% for Actinic Keratosis. Completed, enrolled 168 participants across 16 sites.

Detailed Summary

In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited States
CollaboratorsAthenex, Inc.

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 20, 2016
Enrollment StartApr 11, 2016
Primary CompletionJan 11, 2017
Study CompletionDec 22, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.0 years ago

Interventions

50 mg of KX2-391 Ointment 1%drug

Dose: 50 mg; Route of administration: Topical

50 mg of KX2-391 Ointment 1%drug

Dose: 50 mg; Route of administration: Topical